Pamrevlumab - FibroGen

Drug Profile

Pamrevlumab - FibroGen

Alternative Names: Anti-CTGF antibody; FG-3019

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Idiopathic pulmonary fibrosis; Pancreatic cancer
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies; Glioblastoma; Glomerulonephritis; Hepatic fibrosis

Most Recent Events

  • 07 Aug 2018 FibroGen plans a phase III trial in Idiopathic pulmonary fibrosis in early 2019
  • 07 Aug 2018 FibroGen plans a pivotal trial in Pancreatic cancer in early 2019
  • 04 Jun 2018 Safety and efficacy data from a phase I/II trial in Pancreatic cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top